BiotechTube

Dexamethasone + Prednisolone Acetate Ophthalmic

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Cataract

Conditions

Cataract

Trial Timeline

Jan 4, 2022 → Feb 1, 2026

NCT ID
NCT05191706

About Dexamethasone + Prednisolone Acetate Ophthalmic

Dexamethasone + Prednisolone Acetate Ophthalmic is a approved stage product being developed by EyePoint Pharmaceuticals for Cataract. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05191706. Target conditions include Cataract.

What happened to similar drugs?

9 of 19 similar drugs in Cataract were approved

Approved (9) Terminated (3) Active (8)
✅Prednisolone acetateNovartisApproved
✅Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
✅Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
✅Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved
✅Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved
✅Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic EmulsionOcular TherapeutixApproved
✅Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05191706ApprovedRecruiting

Competing Products

20 competing products in Cataract

See all competitors
ProductCompanyStageHype Score
ISV-305Sun PharmaceuticalPhase 3
40
ISV-303 + Bromday™Sun PharmaceuticalPhase 2
35
ISV-305Sun PharmaceuticalPhase 3
40
DE-108 + Levofloxacin 0.5%Santen PharmaceuticalPhase 3
40
Prednisolone acetateNovartisApproved
43
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
37
Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
37
Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%Ocular TherapeutixPhase 3
34
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]Ocular TherapeutixPhase 2/3
24
Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved
37
Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved
37
Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic EmulsionOcular TherapeutixApproved
29
DexycuEyePoint PharmaceuticalsPhase 3
26
Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved
37
DexycuEyePoint PharmaceuticalsPhase 3
26
DEXYCU (dexamethasone intraocular suspension) 9%.EyePoint PharmaceuticalsPre-clinical
20
Bimatoprost Implant System (High Dose) + Bimatoprost Implant System (Low Dose) + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 1/2
30
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
41
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
41
OMS302 + OMS302-PE + VehicleOmeros CorporationPhase 1/2
26